

# Joshua T Cohen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8012525/publications.pdf>

Version: 2024-02-01

150  
papers

7,516  
citations

76322

40  
h-index

56717

83  
g-index

154  
all docs

154  
docs citations

154  
times ranked

10407  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Updating Cost-Effectiveness â€” The Curious Resilience of the \$50,000-per-QALY Threshold. <i>New England Journal of Medicine</i> , 2014, 371, 796-797.   | 27.0 | 1,784     |
| 2  | Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2007, 10, 1-269.                                       | 6.5  | 741       |
| 3  | Does Preventive Care Save Money? <i>Health Economics and the Presidential Candidates</i> . <i>New England Journal of Medicine</i> , 2008, 358, 661-663.   | 27.0 | 354       |
| 4  | A Quantitative Riskâ€”Benefit Analysis of Changes in Population Fish Consumption. <i>American Journal of Preventive Medicine</i> , 2005, 29, 325-325.   | 3.0  | 197       |
| 5  | A Quantitative Analysis of Fish Consumption and Coronary Heart Disease Mortality. <i>American Journal of Preventive Medicine</i> , 2005, 29, 335-346.   | 3.0  | 161       |
| 6  | A Quantitative Analysis of Prenatal Intake of n-3 Polyunsaturated Fatty Acids and Cognitive Development. <i>American Journal of Preventive Medicine</i> , 2005, 29, 366-366.  | 3.0  | 149       |
| 7  | Screening for Sudden Cardiac Death in the Young. <i>Circulation</i> , 2011, 123, 1911-1918.   | 1.6  | 137       |
| 8  | Noncancer Risk Assessment: A Probabilistic Alternative to Current Practice. <i>Human and Ecological Risk Assessment (HERA)</i> , 1996, 2, 79-102.   | 3.4  | 133       |
| 9  | Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1271-1277.                                       | 2.8  | 126       |
| 10 | A Quantitative Analysis of Prenatal Methyl Mercury Exposure and Cognitive Development. <i>American Journal of Preventive Medicine</i> , 2005, 29, 353-353.  | 3.0  | 119       |
| 11 | QALYs in 2018â€”Advantages and Concerns. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2473.   | 7.4  | 113       |
| 12 | Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. <i>Alzheimer's and Dementia</i> , 2013, 9, 30-38.   | 0.8  | 112       |
| 13 | Vascular Access Choice in Incident Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 183-191.   | 6.1  | 110       |
| 14 | Willingnessâ€”toâ€”pay for predictive tests with no immediate treatment implications: a survey of US residents. <i>Health Economics (United Kingdom)</i> , 2012, 21, 238-251.   | 1.7  | 109       |
| 15 | Perspective and Costing in Cost-Effectiveness Analysis, 1974â€”2018. <i>Pharmacoeconomics</i> , 2020, 38, 1135-1145.  | 3.3  | 109       |
| 16 | A COMPREHENSIVE EVALUATION OF THE POTENTIAL HEALTH RISKS ASSOCIATED WITH OCCUPATIONAL AND ENVIRONMENTAL EXPOSURE TO STYRENE. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2002, 5, 1-263. | 6.5  | 108       |
| 17 | Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. <i>Value in Health</i> , 2018, 21, 759-761.  | 0.3  | 108       |
| 18 | A Quantitative Analysis of Fish Consumption and Stroke Risk. <i>American Journal of Preventive Medicine</i> , 2005, 29, 347-352.  | 3.0  | 103       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | A Systematic Review of the Evidence Concerning the Economic Impact of Employee-Focused Health Promotion and Wellness Programs. <i>Journal of Occupational and Environmental Medicine</i> , 2013, 55, 209-222. | 1.7 | 88        |
| 20 | The Changing Face of the Cost-Utility Literature, 1990â€“2012. <i>Value in Health</i> , 2015, 18, 271-277.  | 0.3 | 85        |
| 21 | Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 168, 161.   | 3.9 | 85        |
| 22 | Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A. <i>Human and Ecological Risk Assessment (HERA)</i> , 2004, 10, 875-921.                                  | 3.4 | 83        |
| 23 | Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. <i>Journal of Vascular Surgery</i> , 2012, 56, 1015-1024.e1.  | 1.1 | 83        |
| 24 | When Is Evidence Sufficient?. <i>Health Affairs</i> , 2005, 24, 93-101.   | 5.2 | 76        |
| 25 | Electrocardiogram Screening for Disorders That Cause Sudden Cardiac Death in Asymptomatic Children: A Meta-analysis. <i>Pediatrics</i> , 2012, 129, e999-e1010.   | 2.1 | 73        |
| 26 | When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. <i>PLoS Medicine</i> , 2017, 14, e1002397.               | 8.4 | 68        |
| 27 | A Revised Economic Analysis of Restrictions on the Use of Cell Phones While Driving. <i>Risk Analysis</i> , 2003, 23, 5-17.   | 2.7 | 67        |
| 28 | 30 Years of Pharmaceutical Cost-Utility Analyses. <i>Pharmacoeconomics</i> , 2009, 27, 861-872.   | 3.3 | 67        |
| 29 | Dementia Diagnosis Disparities by Race and Ethnicity. <i>Medical Care</i> , 2021, 59, 679-686.  | 2.4 | 64        |
| 30 | A clinical and economic evaluation of enteral nutrition. <i>Current Medical Research and Opinion</i> , 2011, 27, 413-422.   | 1.9 | 62        |
| 31 | Dependence as a unifying construct in defining Alzheimer's disease severity. <i>Alzheimer's and Dementia</i> , 2010, 6, 482-493.  | 0.8 | 61        |
| 32 | A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. <i>PLoS ONE</i> , 2016, 11, e0168512.  | 2.5 | 61        |
| 33 | The Empirical Basis for Determinations of Medical Futility. <i>Journal of General Internal Medicine</i> , 2010, 25, 1083-1089.  | 2.6 | 56        |
| 34 | Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. <i>Genetics in Medicine</i> , 2012, 14, 663-669.   | 2.4 | 56        |
| 35 | Costs and Benefits of Targeted Screening for Causes of Sudden Cardiac Death in Children and Adolescents. <i>Circulation</i> , 2012, 125, 2621-2629.   | 1.6 | 55        |
| 36 | Comparative Effectiveness of ST-Segmentâ€“Elevation Myocardial Infarction Regionalization Strategies. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 506-513.                             | 2.2 | 51        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | The influence of time horizon on results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 615-623.  | 1.4  | 51        |
| 38 | The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 75-83.  | 2.1  | 44        |
| 39 | Decision analytic models for Alzheimer's disease: State of the art and future directions. <i>Alzheimer's and Dementia</i> , 2008, 4, 212-222.  | 0.8  | 41        |
| 40 | Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1174-1178.   | 0.8  | 41        |
| 41 | Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. <i>Value in Health</i> , 2017, 20, 200-205.  | 0.3  | 39        |
| 42 | Fuels for Urban Transit Buses: A Cost-Effectiveness Analysis. <i>Environmental Science &amp; Technology</i> , 2003, 37, 1477-1484.   | 10.0 | 37        |
| 43 | Comparing Patient Access to Pharmaceuticals in the UK and US. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 177-187.  | 2.1  | 36        |
| 44 | Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , 2015, 125, 1866-1869.  | 1.4  | 32        |
| 45 | Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. <i>Value in Health</i> , 2015, 18, 308-314.  | 0.3  | 32        |
| 46 | Racial and Ethnic Differences in Knowledge About One's Dementia Status. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1763-1770.   | 2.6  | 32        |
| 47 | Diesel vs. compressed natural gas for school buses: a cost-effectiveness evaluation of alternative fuels. <i>Energy Policy</i> , 2005, 33, 1709-1722.  | 8.8  | 30        |
| 48 | Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1823-1829. | 2.0  | 30        |
| 49 | The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .   | 6.3  | 29        |
| 50 | Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. <i>Journal of General Internal Medicine</i> , 2020, 35, 2629-2636.   | 2.6  | 29        |
| 51 | Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. <i>Health Affairs</i> , 2021, 40, 53-61.   | 5.2  | 29        |
| 52 | Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. <i>Health Affairs</i> , 2015, 34, 253-260.  | 5.2  | 28        |
| 53 | Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019, 14, e0205633.  | 2.5  | 27        |
| 54 | Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia. <i>JAMA Network Open</i> , 2022, 5, e2216260.   | 5.9  | 27        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | The development of a stochastic physiologically-based pharmacokinetic model for lead. <i>Science of the Total Environment</i> , 2001, 274, 15-19.  | 8.0  | 26        |
| 56 | Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 96-103.                                       | 0.5  | 26        |
| 57 | Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. <i>Genetics in Medicine</i> , 2022, 24, 1349-1361.  | 2.4  | 25        |
| 58 | Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.   | 1.1  | 24        |
| 59 | Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality. <i>Health Affairs</i> , 2010, 29, 1523-1531.  | 5.2  | 23        |
| 60 | Rethink chemical risk assessments. <i>Nature</i> , 2012, 489, 27-28.   | 27.8 | 23        |
| 61 | Unintended Benefits: The Potential Economic Impact Of Addressing Risk Factors To Prevent Alzheimer's Disease. <i>Health Affairs</i> , 2014, 33, 547-554.   | 5.2  | 22        |
| 62 | The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 931-940. | 1.4  | 21        |
| 63 | Life Years Lost at Hazardous Waste Sites: Remediation Worker Fatalities vs. Cancer Deaths to Nearby Residents. <i>Risk Analysis</i> , 1997, 17, 419-425.   | 2.7  | 20        |
| 64 | What's More Dangerous, Your Aspirin Or Your Car? Thinking Rationally About Drug Risks (And) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50   | 5.2  | 20        |
| 65 | Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1972.  | 7.4  | 20        |
| 66 | Illustrating Potential Efficiency Gains from Using Cost-Effectiveness Evidence to Reallocate Medicare Expenditures. <i>Value in Health</i> , 2013, 16, 629-638.  | 0.3  | 19        |
| 67 | Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. <i>Value in Health</i> , 2017, 20, 193-199.   | 0.3  | 18        |
| 68 | Low-value services in value-based insurance design. <i>American Journal of Managed Care</i> , 2010, 16, 280-6.   | 1.1  | 18        |
| 69 | An Arsenic Exposure Model: Probabilistic Validation Using Empirical Data. <i>Human and Ecological Risk Assessment (HERA)</i> , 1998, 4, 341-377.   | 3.4  | 17        |
| 70 | Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018, 182, 212-221.  | 2.5  | 17        |
| 71 | Health Trade-offs from Policies to Alter Fish Consumption. <i>American Journal of Preventive Medicine</i> , 2005, 29, 324-324.   | 3.0  | 16        |
| 72 | What is the value of oncology medicines?. <i>Nature Biotechnology</i> , 2010, 28, 1160-1163.   | 17.5 | 16        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Evaluation of the Economic Burden of Diseases Associated With Poor Nutrition Status. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 35S-41S.  | 2.6 | 16        |
| 74 | Patient Variability Seldom Assessed in Cost-effectiveness Studies. <i>Medical Decision Making</i> , 2018, 38, 487-494.  | 2.4 | 16        |
| 75 | Estimated Impact of Targeted Pre-Exposure Prophylaxis: Strategies for Men Who Have Sex with Men in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1592.                    | 2.6 | 16        |
| 76 | Cardiac Screening Prior to Stimulant Treatment of ADHD: A Survey of US-Based Pediatricians. <i>Pediatrics</i> , 2012, 129, 222-230.   | 2.1 | 15        |
| 77 | Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S34-S48.                                   | 0.9 | 15        |
| 78 | Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. <i>Gates Open Research</i> , 2018, 2, 5.  | 1.1 | 15        |
| 79 | Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e948-e956. | 2.5 | 14        |
| 80 | Dementia diagnosis disparities by race and ethnicity. <i>Alzheimer's and Dementia</i> , 2020, 16, e043183.  | 0.8 | 14        |
| 81 | The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses. <i>Medical Decision Making</i> , 2010, 30, 314-319.   | 2.4 | 13        |
| 82 | Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 513-522.                                   | 1.4 | 13        |
| 83 | Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia. <i>Medical Care</i> , 2016, 54, 380-385.   | 2.4 | 13        |
| 84 | ICER's Revised Value Assessment Framework for 2017-2019: A Critique. <i>Pharmacoeconomics</i> , 2017, 35, 977-980.  | 3.3 | 13        |
| 85 | Are low and middle-income countries prioritising high-value healthcare interventions?. <i>BMJ Global Health</i> , 2020, 5, e001850.   | 4.7 | 13        |
| 86 | Do Cost-Effectiveness Analyses Account for Drug Generization? A Literature Review and Assessment of Implications. <i>Value in Health</i> , 2022, 25, 59-68.   | 0.3 | 13        |
| 87 | Reexamining the Emperor's New Clothes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 134-137.  | 2.2 | 12        |
| 88 | Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 595-603.   | 1.4 | 12        |
| 89 | A primer on cost-effectiveness analyses for vascular surgeons. <i>Journal of Vascular Surgery</i> , 2012, 55, 1794-1800.  | 1.1 | 12        |
| 90 | Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response. <i>Medical Care</i> , 2017, 55, 912-914.  | 2.4 | 12        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Measuring "Economic Effects" in Valuing Therapies: An Application to COVID-19 in China. <i>Value in Health</i> , 2020, 23, 1405-1408.  | 0.3  | 12        |
| 92  | Preparing the health care system to pay for new Alzheimer's drugs. <i>Alzheimer's and Dementia</i> , 2020, 16, 1568-1570.  | 0.8  | 12        |
| 93  | Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. <i>Pharmacoeconomics</i> , 2022, 40, 699-714.  | 3.3  | 12        |
| 94  | Title is missing!. <i>Environmental Geochemistry and Health</i> , 1998, 20, 61-66.   | 3.4  | 11        |
| 95  | Using Decision Analysis To Better Evaluate Pediatric Clinical Guidelines. <i>Health Affairs</i> , 2008, 27, 1467-1475.   | 5.2  | 11        |
| 96  | Trends of cost-effectiveness studies in sleep medicine. <i>Sleep Medicine</i> , 2019, 53, 176-180.   | 1.6  | 11        |
| 97  | Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 627-638.           | 0.9  | 11        |
| 98  | Drug-Pricing Debate Redux " Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?. <i>New England Journal of Medicine</i> , 2021, 385, 1923-1924.   | 27.0 | 11        |
| 99  | Unintended consequences of the potential phase-out of gamma irradiation. <i>F1000Research</i> , 2018, 7, 348.  | 1.6  | 10        |
| 100 | Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. <i>Medical Decision Making</i> , 2017, 37, 790-801.  | 2.4  | 9         |
| 101 | Publication of Decision Model Source Code: Attitudes of Health Economics Authors. <i>Pharmacoeconomics</i> , 2019, 37, 1409-1410.  | 3.3  | 9         |
| 102 | Cost-Effectiveness of Cardiovascular Disease Spending. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2123-2124.   | 2.8  | 8         |
| 103 | A Role for Research. <i>American Journal of Preventive Medicine</i> , 2013, 44, S12-S15.   | 3.0  | 8         |
| 104 | Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2015, 109, 379-385.            | 1.8  | 8         |
| 105 | The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. <i>Health Research Policy and Systems</i> , 2016, 14, 86. | 2.8  | 8         |
| 106 | Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study. <i>Pharmacoeconomics</i> , 2016, 34, 1255-1265.  | 3.3  | 8         |
| 107 | Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. <i>Health Affairs</i> , 2019, 38, 60-67.  | 5.2  | 8         |
| 108 | A Call for Open-Source Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2018, 168, 529.   | 3.9  | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Survey of United States Child and Adolescent Psychiatrists' Cardiac Screening Practices Prior to Starting Patients on Stimulants. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 375-384.          | 1.3 | 6         |
| 110 | 2011: National Estimates of Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer's Disease and Related Dementias. <i>Alzheimer's and Dementia</i> , 2016, 12, P253.                         | 0.8 | 6         |
| 111 | FDA's Proposed Ban on Trans Fats: How Do the Costs and Benefits Stack Up?. <i>Clinical Therapeutics</i> , 2014, 36, 322-327.  | 2.5 | 5         |
| 112 | The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 494-508. | 1.3 | 5         |
| 113 | Cost-effectiveness analysis of three algorithms for diagnosing primary ciliary dyskinesia: a simulation study. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 142.  | 2.7 | 5         |
| 114 | Hospital Care at Home: Better, Cheaper, Faster?. <i>Annals of Internal Medicine</i> , 2020, 172, 145.   | 3.9 | 5         |
| 115 | Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.. <i>Oncologist</i> , 2020, 25, e1117-e1119.   | 3.7 | 5         |
| 116 | Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. <i>Vaccine</i> , 2021, 39, 6727-6734.   | 3.8 | 5         |
| 117 | Author's response: Risks and Benefits of Seafood Consumption. <i>American Journal of Preventive Medicine</i> , 2006, 30, 441-443.   | 3.0 | 4         |
| 118 | A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. <i>Value in Health</i> , 2018, 21, 400-406.  | 0.3 | 4         |
| 119 | The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. <i>Value in Health</i> , 2022, 25, 1336-1343.  | 0.3 | 4         |
| 120 | Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Medical Economic Perspective. <i>American Journal of Kidney Diseases</i> , 2007, 50, 362-365.  | 1.9 | 3         |
| 121 | Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. <i>Journal of Medical Economics</i> , 2011, 14, 187-193.   | 2.1 | 3         |
| 122 | Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016, 2016, 1-6.                                   | 1.7 | 3         |
| 123 | Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , 2018, 59, 1976-1980.  | 1.3 | 3         |
| 124 | Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?. <i>Value in Health</i> , 2019, 22, 1396-1401.  | 0.3 | 3         |
| 125 | Value-based drug pricing in the Biden era: Opportunities and prospects. <i>Health Services Research</i> , 2021, 56, 1093-1099.  | 2.0 | 3         |
| 126 | The use of Monte Carlo simulation techniques to predict population blood lead levels. <i>Environmental Geochemistry and Health</i> , 1994, 16-16, 197-215.  | 3.4 | 2         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Imputing Productivity Gains From Clinical Trials. <i>Journal of Occupational and Environmental Medicine</i> , 2012, 54, 826-833.   | 1.7 | 2         |
| 128 | Economic Evaluation in Adolescent and Young Adult Cancer: Methodological Considerations and the State of the Science. <i>Pediatric Oncology</i> , 2017, , 779-799.   | 0.5 | 2         |
| 129 | Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. <i>Acta Diabetologica</i> , 2021, 58, 707-722.  | 2.5 | 2         |
| 130 | Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12068-12068. | 1.6 | 2         |
| 131 | Pediatric Lipid Screening and Treatment for Cardiovascular Disease Prevention: An Ounce or a Pound?. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 261-269.  | 2.0 | 1         |
| 132 | Cost Estimation of First-Line Antiretroviral Therapy with Zidovudine/Stavudine as the Nucleoside Backbone in India. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 180-184.                                       | 1.5 | 1         |
| 133 | Cost-Effective but Bad for Health? Hepatitis C Treatment, Moral Hazard, and Opportunity Cost. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 838-840.   | 4.4 | 1         |
| 134 | Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 169, 200.  | 3.9 | 1         |
| 135 | Optimizing Decision Making in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 265-273.   | 0.2 | 1         |
| 136 | Is the high cost of CML care "worth it"?. <i>Journal of Clinical Oncology</i> , 2015, 33, e17801-e17801.   | 1.6 | 1         |
| 137 | The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20019-e20019.   | 1.6 | 1         |
| 138 | Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 235-241.  | 2.1 | 1         |
| 139 | The Author's Reply. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 270-272.  | 2.1 | 0         |
| 140 | Reducing Cardiovascular Disease. <i>Diabetes Care</i> , 2008, 31, 1708-1709.   | 8.6 | 0         |
| 141 | Letter to the Editor. <i>Risk Analysis</i> , 2010, 30, 1457-1458.  | 2.7 | 0         |
| 142 | Price and value in cancer care. <i>Cancer</i> , 2015, 121, 4097-4098.  | 4.1 | 0         |
| 143 | 3385 TARGETING DIABETES PREVENTION PROGRAMS: INDIVIDUAL RISK-BASED HEALTH ECONOMIC ANALYSIS. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 155-156.  | 0.6 | 0         |
| 144 | Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8517-8517.                 | 1.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. <i>Blood</i> , 2015, 126, 2635-2635.   | 1.4 | 0         |
| 146 | Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review. <i>Blood</i> , 2016, 128, 3564-3564.  | 1.4 | 0         |
| 147 | Validity and reliability of four value frameworks for cancer drugs.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6603-6603.   | 1.6 | 0         |
| 148 | Network meta-analysis of adjuvant chemotherapy in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12071-e12071.  | 1.6 | 0         |
| 149 | Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6512-6512. | 1.6 | 0         |
| 150 | Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18887-e18887.   | 1.6 | 0         |